Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Usana Health Sciences (USNA) over the last 15 years, with Q3 2025 value amounting to -$6.1 million.

  • Usana Health Sciences' Net Cash Flow fell 12263.44% to -$6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$216.0 million, marking a year-over-year decrease of 50568.59%. This contributed to the annual value of -$142.5 million for FY2024, which is 42083.77% down from last year.
  • According to the latest figures from Q3 2025, Usana Health Sciences' Net Cash Flow is -$6.1 million, which was down 12263.44% from -$30.6 million recorded in Q2 2025.
  • Usana Health Sciences' Net Cash Flow's 5-year high stood at $37.0 million during Q4 2022, with a 5-year trough of -$176.4 million in Q4 2024.
  • Moreover, its 5-year median value for Net Cash Flow was $1.7 million (2024), whereas its average is -$14.4 million.
  • As far as peak fluctuations go, Usana Health Sciences' Net Cash Flow skyrocketed by 154261.46% in 2023, and later tumbled by 101132.29% in 2024.
  • Usana Health Sciences' Net Cash Flow (Quarter) stood at -$53.9 million in 2021, then skyrocketed by 168.7% to $37.0 million in 2022, then tumbled by 47.72% to $19.4 million in 2023, then crashed by 1011.32% to -$176.4 million in 2024, then skyrocketed by 96.52% to -$6.1 million in 2025.
  • Its Net Cash Flow stands at -$6.1 million for Q3 2025, versus -$30.6 million for Q2 2025 and -$2.9 million for Q1 2025.